SCHEDULE: Janus Henderson Maintains Significant Stake in Monopar

Janus Henderson Group plc and its affiliates report a 19.5% beneficial ownership in Monopar Therapeutics Inc. common stock.

Summary

• Janus Henderson Group plc, along with its subsidiary Janus Henderson Biotech Innovation Master Fund Ltd, filed an Amendment No. 4 to Schedule 13G.
• Janus Henderson Group plc beneficially owns 1,287,368 shares of Monopar Therapeutics Inc. common stock, representing 19.5% of the class.
• Janus Henderson Biotech Innovation Master Fund Ltd beneficially owns 1,105,471 shares, representing 16.7% of the class.
• Both entities hold shared voting and shared dispositive power over their respective shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a significant and continued institutional ownership by Janus Henderson Group plc in Monopar Therapeutics Inc., which can be interpreted as a positive signal of investor confidence. The stake of 19.5% is substantial.

Positives

• Janus Henderson Group plc, a prominent institutional investor, maintains a substantial beneficial ownership of 19.5% in Monopar Therapeutics Inc., indicating continued confidence in the company's prospects.

Risks

• The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, mitigating immediate control-related risks from this specific shareholder.

Future Outlook

This filing does not contain forward-looking statements or guidance from Monopar Therapeutics Inc. It is a disclosure of beneficial ownership by an institutional investor.

Management Comments

• Kristin Mariani, Head of North America Compliance, CCO, certified that the information set forth in the statement is true, complete, and correct to the best of her knowledge and belief.
• The reporting persons certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Industry Context

This filing reflects an institutional investor's continued significant stake in a biotechnology company. Such substantial holdings by specialized funds like Janus Henderson Biotech Innovation Master Fund Ltd are common in the biotech sector, where long-term investment in promising therapies is typical.

Stakeholder Impact

• Shareholders: The continued significant ownership by a major institutional investor like Janus Henderson may provide a level of confidence and stability, potentially influencing investor sentiment positively.

Key Dates

Keywords

Monopar Therapeutics, Janus Henderson, Institutional Ownership, Biotech, Common Stock, SEC Filing, Schedule 13G, Investment Adviser